Get the Daily Brief
Latest Biotech News
Cellarity publishes cell‑state drug framework in Science — AI meets transcriptomics
Cellarity published a Science manuscript outlining a framework that integrates large transcriptomic datasets with AI modeling to identify compounds that correct pathological cell states. The...
10x, Roche and Prognosys sue Illumina — patent fights escalate in spatial and single‑cell
10x Genomics, joined by Roche Sequencing Solutions and licensor Prognosys, filed two federal lawsuits accusing Illumina of infringing on nine patents covering spatial biology and single‑cell...
Biogen bets $1B on Vanqua’s C5aR1 drug: upfront $70M, $990M in milestones
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front with as much as $990 million in downstream payments. The agreement hands...
Lilly rescues Adverum: gene-therapy buy priced below market with CVR upside
Eli Lilly agreed to acquire cash-strapped Adverum in a deal that secures ixo-vec, an AAV-based intravitreal gene therapy in Phase 3 for wet age-related macular degeneration. The transaction values...
FDA clears new nonhormonal menopause drugs: elinzanetant and Bayer’s Lynkuet win approval
The FDA approved elinzanetant, a nonhormonal agent shown to reduce hot flashes and night sweats in clinical trials, and separately cleared Bayer’s Lynkuet as the first dual neurokinin-targeted...
Tango’s PRMT5 data clear path to pivotal study – $225M bridge financing follows
Tango Therapeutics reported phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor engineered for MTAP‑deleted tumors, that the company said justify a planned pivotal study...
Inhibrx posts registrational win in rare chondrosarcoma – BLA plans underway
Inhibrx reported that its monoclonal antibody ozekibart hit the primary endpoint in a registrational phase II trial for advanced or metastatic unresectable chondrosarcoma, producing significant...
Deep learning hunts antibiotics: Nature Biotech papers deliver novel scaffolds
Two independent Nature Biotechnology reports demonstrated deep‑learning approaches that accelerate antibacterial discovery by prioritizing novel chemical scaffolds from high‑throughput and...
Retron editors resurface: metagenomic search yields new retron‑based gene editors
Researchers mined bacterial and archaeal metagenomes to identify retron elements that can be repurposed as self‑priming DNA editors compatible with CRISPR systems. The work validated candidate...
Personalized CRISPR in months: Baby KJ’s bespoke gene‑editing program shows the model
A rapid, multi‑partner effort produced a personalized CRISPR gene therapy for Baby KJ’s urea cycle disorder, converting academic discovery to a clinical candidate within months. The coordinated...
Genomic‑method advances: ultra‑mild bisulfite sequencing and benchmarking toolkit EasyGeSe
Two methodological advances aim to expand reliable genomic assays on limited clinical material. Ultra‑mild bisulfite sequencing (UMBS) reduces DNA damage during methylation profiling, boosting...
Cellarity publishes AI framework for cell‑state medicines in Science: transcriptomics meets models
Cellarity published a Science manuscript outlining a framework that integrates multi‑omic transcriptomic datasets with AI models to discover cell‑state‑correcting therapeutics. The approach trains...
Biogen bets on innate immunity: $70M deal for Vanqua's C5aR1 program
Biogen in-licensed Vanqua Bio’s preclinical C5aR1 antagonist for $70 million up front, with up to $990 million in milestone payments and tiered royalties. The deal gives Biogen exclusive worldwide...
FDA clears nonhormonal option: elinzanetant approved for hot flashes
The FDA granted approval to elinzanetant, a nonhormonal agent shown in multi‑national trials to reduce vasomotor symptoms of menopause, including hot flashes and night sweats. Regulatory documents...
GSK’s Blenrep comeback: FDA clears a narrower U.S. label
The FDA has approved GSK’s antibody‑drug conjugate Blenrep for a limited multiple myeloma indication after the drug failed a prior confirmatory trial and was pulled in 2022. The agency cleared...
Lilly buys Adverum... one‑time gene therapy prize for wet AMD
Eli Lilly agreed to acquire cash‑strapped Adverum for an upfront cash consideration and contingent value rights tied to the success of Adverum’s phase‑3 AAV gene therapy ixo‑vec for wet...
Inhibrx posts registrational win: phase II data push BLA talk
Inhibrx reported that its monoclonal antibody ozekibart met the primary endpoint in a registrational phase II study for unresectable or metastatic chondrosarcoma, producing statistically...
Deep learning revs antibiotic discovery: two Nature Biotechnology reads
Two independent Nature Biotechnology papers detail how deep‑learning approaches accelerated antibacterial discovery. One study combined phenotypic screening with deep neural networks to prioritize...
LNP anatomy revealed: biophysics links particle shape to delivery
A multidisciplinary team at the University of Pennsylvania, Brookhaven National Laboratory and collaborators mapped lipid nanoparticle (LNP) structures and linked distinct morphologies to delivery...
Retrons retooled: metagenomes yield new retron gene editors
Researchers mined bacterial and archaeal metagenomes to identify self‑priming retrons that function as DNA donors and adapted several as programmable gene editors compatible with CRISPR systems....